Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AGXSWX:RO -0.70%79 Price-to-Tangible-Book is 52.30 as of Aug. 14, 2026, which is 55% above its 10-year median of 33.69. GuruFocus rates XSWX:RO with a GF Score™ of 79/100 and a GF Value™ of CHF271.10 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 836 Drug Manufacturers companies, Roche Holding AG ranks worse than 99.04% on this metric.
The historical rank and industry rank for Roche Holding AG's Price-to-Tangible-Book or its related term are showing as below:
XSWX:RO'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 17.49 Med: 33.69 Max: 340.06
Current: 51.58
During the past 13 years, Roche Holding AG's highest Price to Tangible Book Ratio was 340.06. The lowest was 17.49. And the median was 33.69.
XSWX:RO's Price-to-Tangible-Book is ranked worse than 99.04% of 836
companies
in the Drug Manufacturers industry
Industry Median: 2.255
vs XSWX:RO: 51.58
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Roche Holding AG Price-to-Tangible-Book Related Terms
Roche Holding AG Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Roche Holding AG (XSWX:RO) has a Price-to-Tangible-Book of 52.30 as of Aug. 14, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Roche Holding AG and its competitors. This is 55% above median its historical median of 33.69. Over the past decade, Roche Holding AG's Price-to-Tangible-Book has ranged from 17.49 to 340.06. According to the industry distribution chart, Roche Holding AG ranks #828 out of 836 companies in the Drug Manufacturers industry, placing it in the top 99%.
Is Roche Holding AG's Price-to-Tangible-Book too high?
Roche Holding AG's current Price-to-Tangible-Book of 52.30 is 55% above median its 10-year median of 33.69. Over the past 10 years, this metric has ranged from a low of 17.49 to a high of 340.06. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.26. Roche Holding AG's value of 52.30 is 2219.3% above this industry median. Based on the distribution chart, Roche Holding AG ranks #828 out of 836 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Price-to-Tangible-Book compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #828 out of 836 companies for Price-to-Tangible-Book. This places Roche Holding AG in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.26. Roche Holding AG's value of 52.30 is 2219.3% above this benchmark. Historically, Roche Holding AG's own Price-to-Tangible-Book has ranged from 17.49 to 340.06 over the past decade. While the company's 10-year median is 33.69 vs. the industry median of 2.26, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.26, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Price-to-Tangible-Book of 52.30 is 2219.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Price-to-Tangible-Book is 52.30, which is 55% above median its own 10-year median of 33.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF271.10, compared to a current price of CHF367.80 — trading 35.7% above its estimated fair value. The current Price-to-Tangible-Book is 52.30, which is 55% above median its 10-year median of 33.69 and 2219.3% above the Drug Manufacturers industry median of 2.26. Roche Holding AG's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Price-to-Tangible-Book is 52.30 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF367.80 is trading 35.7% above its estimated GF Value™ of CHF271.10.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for XSWX:RO:
Price-to-Tangible-Book: 52.30 (55% above median its 10-year median of 33.69)
GF Value™: CHF271.10 vs. price of CHF367.80 (35.7% above fair value)
Industry Position: 2219.3% above the Drug Manufacturers median (#828 of 836)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score
Get the complete analysis for XSWX:RO
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
